Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs. [PDF]
Cancers (Basel), 2021 Background: Rodent cancer models have limitations in predicting efficacy, tolerability and accompanying biomarkers of ICIs in humans. Companion dogs suffering from neoplastic diseases have gained attention as a highly relevant translational disease model.
Pantelyushin S +9 more
europepmc +5 more sources
Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. [PDF]
J Cancer Res Clin Oncol, 2018 Kaufman HL +7 more
europepmc +3 more sources
Role of immune checkpoint blockers in patients with EGFR mutation. [PDF]
Transl Lung Cancer Res, 2018 Ward J, Morgensztern D.
europepmc +4 more sources
Emerging Therapeutic Agents for Colorectal Cancer
Molecules, 2021 There are promising new therapeutic agents for CRC patients, including novel small-molecule inhibitors and immune checkpoint blockers. We focused on emerging CRC’s therapeutic agents that have shown the potential for progress in clinical practice.
Marianna Nalli +4 more
doaj +1 more source
A Case of Acute Heart Failure due to Immune Checkpoint Blocker Nivolumab.
Cardiology Research, 2019 Immune checkpoint inhibitors can be potentially cardiotoxic. It has not been frequently reported in the literature. Cardiomyopathy with these agents can have early onset and may start with non-specific symptoms like fatigue, weakness before presenting with obvious features of acute heart failure.
Munish Sharma +2 more
openalex +5 more sources
A tumor-targeted immune checkpoint blocker [PDF]
Proceedings of the National Academy of Sciences, 2019 Significance Current immune checkpoint inhibitors are not tumor specific and induce systemic immune activation in other tissues and organs. Combination immunotherapies further amplify these toxicities, which limit their clinical application.
Yuhan, Zhang +11 more
openaire +2 more sources
Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers [PDF]
Clinical and Experimental Immunology, 2020 Summary Immune checkpoint blockers improve the overall survival of a limited number of patients among different cancers. Identifying pathways that influence the immunological and clinical response to treatment is critical to improve the therapeutic efficacy and predict clinical responses.
M Segovia +4 more
openaire +3 more sources
Frontiers in Oncology, 2022 Cervical cancer is one of the women-associated tumors that affects numerous people yearly. It is the fourth most common malignancy in women worldwide.
Haigang Ding +9 more
doaj +1 more source
Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
OncoImmunology, 2023 Checkpoint blockade immunotherapy transforms many types of cancer; however, in the field of metastatic colorectal cancer, checkpoint blockers are only effective in microsatellite-unstable tumors, which represent only a minority of patients ...
Marion Thibaudin, Francois Ghiringhelli
doaj +1 more source
Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience. [PDF]
Cancers (Basel)Purpose: We report a 10-year experience in cancer therapy with concomitant treatment of percutaneous thermal ablation (PTA) and immune checkpoint blockers (ICBs). Material and methods: This retrospective cohort study included all patients at a single tertiary cancer center who had received ICBs at most 90 days before, or 30 days after, PTA. Feasibility
Bonnet B +10 more
europepmc +3 more sources